Biopharmaceutical Co. To Go Public Via All-Stock Merger
Late-stage biopharmaceutical company Lenz Therapeutics, advised by Wilson Sonsini Goodrich & Rosati PC, on Wednesday announced that it has agreed to merge with gene editing company Graphite Bio Inc., advised by...To view the full article, register now.
Already a subscriber? Click here to view full article